Dietary Status and Impact of Risperidone on Nutritional Balance in Children with Autism: a Pilot Study
Overview
Authors
Affiliations
Background: Risperidone may be effective in improving tantrums, aggression, or self-injurious behaviour in children with autism, but often leads to weight gain.
Method: Using a quantitative Food Frequency Questionnaire (FFQ), we prospectively examined the nutritional intake of 20 children with autism participating in a randomised placebo-controlled trial of risperidone for disruptive behaviours.
Results: At baseline, the mean intakes for macronutrients, vitamins and minerals exceeded Dietary Reference Intakes (DRIs). However there was substantial inter-participant variability, with individual deficiencies (<80% of DRI) in the intake of calcium (9 of 20 participants), pantothenic acid (6 of 20), vitamin D (5 of 20) and vitamin K (8 of 20). For the participants for whom FFQs were available, there was an increase in weight and an increase in vitamin K intake after 2 months of risperidone treatment (n = 9) compared to placebo (n = 8). An additional 4 months of risperidone treatment (n = 8) did not result in significant changes in reported nutritional balance.
Conclusion: These pilot data suggest that treatment with risperidone did not significantly affect the nutritional balance of this small group of children.
Kim J Soa Chongsonyon Chongsin Uihak. 2024; 35(1):51-56.
PMID: 38204735 PMC: 10774563. DOI: 10.5765/jkacap.230063.
Indika N, Frye R, Rossignol D, Owens S, Senarathne U, Grabrucker A J Pers Med. 2023; 13(2).
PMID: 36836486 PMC: 9964499. DOI: 10.3390/jpm13020252.
Mutwalli H, Keeler J, Bektas S, Dhopatkar N, Treasure J, Himmerich H J Psychiatr Res. 2023; 160:137-162.
PMID: 36804110 PMC: 10682412. DOI: 10.1016/j.jpsychires.2023.02.006.
Dong H, Wang B, Feng J, Yue X, Jia F Front Nutr. 2021; 8:748513.
PMID: 34660670 PMC: 8514626. DOI: 10.3389/fnut.2021.748513.
Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis.
Mano-Sousa B, Pedrosa A, Alves B, Galduroz J, Belo V, Chaves V Curr Neuropharmacol. 2020; 19(4):538-552.
PMID: 32469700 PMC: 8206457. DOI: 10.2174/1570159X18666200529151741.